THERANEXUS: Theranexus and BBDF win FDA approval on efficacy

Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor functions, The FDA confirmed that this sole Phase III trial would secure

Related Keywords

United States , Paris , France General , France , Texas , French , Craig Benson , Marie Sebille , Mathieu Charv , Florence Portejoie , Thierry Lambert , Martin Pierre Laurent , Drug Administration , Twitter , Atomic Energy Commission , Division Of Rare Diseases , National Organization For Rare Disorders , Batten Disease Foundation , Beyond Batten Disease Foundation , Rare Diseases , Medical Genetics , Theranexu Chief Medical Officer Marie , Verbal Comprehension Index , Wechsler Intelligence Scale , Unified Batten Disease Rating Scale , French Alternative Energies , Euronext Growth , Rare Disorders , Gefallene Big Techs , Theranexus , Bbdf , Approval , Efficacy , Endpoints , Hase , Trial , Valuate , Thatten , Ln3 , Disease ,